In this video, Ilana Schlam, MD, MPH, discusses current treatment options for patients with early-stage or metastatic triple-negative breast cancer, including recent approvals of antibody-drug conjugates in the first-line setting.
“This is new and this is very exciting, because in all of these trials the [antibody-drug conjugate (ADC)] was compared with chemotherapy and the ADC performed better,” Schlam, breast medical oncologist at Dana-Farber Cancer Institute, said. “So, it’s really important that we know about this and that we start treating the patients with these now standard first-line treatments.
More Hot Topics in Breast Cancer
Read more about
Healio spoke with experts in breast cancer about what to expect from SABCS 2019, developments in diagnosis, advances in treatments, pivotal trials and more highlights from the meeting.
